A Multicenter, III Stage, Randomized Controlled Trail on the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib in Untreated Unresectable and Metastatic Urothelial Carcinoma.

The aim of this study is to see whether the Trilaciclib is safe and effective in slowing down the growth of bladder cancer in patients while taking chemoimmunotherapy.

开始日期2025-10-01

申办/合作机构

中山大学孙逸仙纪念医院

NCT05700448

/ Not yet recruiting临床3期

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

开始日期2025-06-01

申办/合作机构

基石药业

NCT06274879

/ Not yet recruiting临床2期

Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer Undergoing Standard of Care Chemo-immune Checkpoint Inhibitor -Therapy: a Phase II, Multicenter, Randomized and Controlled

The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of chemotherapy (gemcitabine and cisplatin) plus durvalumab (immune-checkpoint-inhibitor, ICI). The main question it aims to answer is whether it is safe to combine chemotherapy (gemcitabine and cisplatin) and immunotherapy (durvalumab) - CICI therapy.
Participants will be assigned to either the control group or the experimental group. In the control group, the standard of care consists of endoscopy with stent placement in the bile duct and CICI, whereas in the experimental group, bRFA will be performed in addition to the standard of care. Participants will be followed up for 6 months, during the follow-up, the stage of the tumor, blood examination, the duration of the stent from the insertion until its failure, adverse events and quality of life will be examined.
Researchers will compare the standard of care alone to the experimental group to see if the additional bRFA procedure causes higher or no difference in adverse events rate.

开始日期2025-06-01

申办/合作机构

Insel Gruppe AG

[+1]

100 项与吉西他滨相关的临床结果

登录后查看更多信息

100 项与吉西他滨相关的转化医学

登录后查看更多信息

100 项与吉西他滨相关的专利（医药）

登录后查看更多信息

29,732

项与吉西他滨相关的文献（医药）

2025-12-31·Molecular & Cellular Oncology

CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549

Article

作者: Ma, Xuan ; Liang, Ai-Ling ; Fu, Tian ; Wang, Wen-Xuan ; Ke, Zhi-Yin ; Wang, Xue-Chun ; Liu, Yong-Jun ; Yin, Hai-Han

The purpose of the study is mainly to investigate anti proliferation of non-small cell lung cancer A549 cells and its mechanism by inhibition of CHK1 expression combined with gemcitabine. The mRNA and protein levels of genes were analyzed by RT-qPCR and Western blot, respectively. Cell viability was detected by CCK-8 assay and clone formation assay. The detection of the cell cycle was used by Annexin V/7-amino-actinomycin D apoptosis detection kit. Analysis of DNA damage was done by immunofluorescence and alkaline comet assay. The results showed that inhibition of CHK1 and gemcitabine combination significantly reduced the proliferation ability of the two cell lines. We also revealed the degradation of full-length PARP and reduced Bcl-2/Bax ratio on increased apoptosis. Inhibition of CHK1 expression leads to DNA damage, induces phosphorylation of γ-H2AX, and affects the repair of homologous recombination ability through Rad51. Mechanistically, gemcitabine increased phosphorylation-ATR and phosphorylation-CHK1, indicating activation of the DNA repair system and ATR-CHK1-CDC25A pathway. Inhibition of CHK1 resulted in increased synthesis of CDK2/Cyclin A2 and CDK2/Cyclin E1 complexes, and more cells entered the subsequent cell cycle, leading to S phase arrest and mitotic catastrophe. We identified inhibition of CHK1 as a potential treatment for NSCLC and confirmed that inhibition of this kinase could overcome acquired gemcitabine resistance.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States

Article

作者: Li, Jia ; Mahmoudjafari, Zahra ; Masaquel, Anthony ; Parisé, Hélène ; Bercaw, Eric ; Bognar, Katalin ; Wang, Si-Tien

BACKGROUND:

Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy (3L+).

METHODS:

A budget impact model was developed for a hypothetical blended commercial/Medicare health plan with 1,000,000 members. Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine, polatuzumab vedotin + bendamustine + rituximab, rituximab + gemcitabine + oxaliplatin, tafasitamab + lenalidomide, and epcoritamab (Epcor). Total costs included those for drugs, wastage, administration, grade ≥3 adverse reactions, and all-grade cytokine release syndrome) and routine care. Market shares were based on internal projections and expert opinions. Total and per-member per-month (PMPM) net budget impacts over 3 years were calculated.

RESULTS:

Approximately nine patients were projected to be eligible for 3L + DLBCL treatment in a health plan of 1,000,000 members. The introduction of glofitamab as a treatment option resulted in estimated total and PMPM cost savings of $728,697 and -$0.0202, respectively, over 3 years. Costs were reduced across all cost categories but particularly in drug costs. Among the newer therapies, total 3-year cost per treated patient was lowest for glofitamab: $226,658 versus Tisa-cel = $564,113; Axi-cel = $540,002; Liso-cel = $516,272; and Epcor = $335,293. Across all sensitivity analyses, the inclusion of glofitamab had minimal PMPM budget impact, ranging from -$0.0256 to -$0.0108.

CONCLUSIONS:

With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years.

2025-12-01·Journal of Gastrointestinal Cancer

Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT)

Article

作者: Naik, Nagendra ; Priyanka, Parul ; Agrawal, Sushma

INTRODUCTION:

Retroperitoneal lymphadenopathy is considered a metastatic disease in GBC; however, some surgical series of radical surgery with enlarged RPLN who underwent RPLN dissection have shown results marginally inferior to those without enlarged RPLN. Radiological RPLN comprises a major proportion of advanced non-metastatic GBC. There is dilemma in the intent of treatment to be offered in such cases. We are reporting our series of outcome of GBC with RPLN treated with first-line CT followed by consolidation CTRT.

MATERIALS AND METHODS:

Non-metastatic locally advanced GBC with good performance status (KPS ≥ 80) were initiated on first-line CT (cisplatin-gemcitabine), and thereafter, responders were evaluated by CECT-angiography and PET-CT scan for resectability. If found unresectable, they were offered consolidation CTRT to a dose of 45 Gy by conventional fractionation (3D-CRT technique) along with concurrent capecitabine at 1250 mg/m² to GBC and regional lymphatics including RPLN. Thereafter, boost dose of 9 Gy/5# was given to GBC only. Response assessment was done using CECT abdomen by RECIST criteria v 1.1. Outcomes (overall survival) of the two groups (RPLN vs non-RPLN) were computed with Kaplan-Meier survival curves and chi-square tests using SPSS v 20.

RESULTS:

Among 189 patients of advanced non-metastatic GBC recruited from 2011 to 2022, 80 had RPLN. The demographic features of both groups were comparable. Overall, 68% of the patients were women, 30% underwent upfront stenting for obstructive jaundice, and 90% had T3 and T4 disease. Only 10% had undergone upfront laparoscopic staging and had pathologically proven RPLN. Forty percent of the patients received four cycles of CT only and 50% of the patients received six cycles or more and 33% received CTRT. By RECIST criteria, 10% vs 16% achieved complete response (CR), 39% vs 41% achieved partial response (PR), 16% vs 15% achieved stable disease (SD), 2.7% vs 6% had disease progression (PD), and 14.5% vs 3.7% were non-evaluable in non-RPLN group vs RPLN group, respectively. 12% vs 6% could undergo radical surgery in non-RPLN group vs RPLN group (p = 0.03). The median OS was 9 months (95% CI 7.6-10.3 months) vs 10 months (95% CI 8-9.8 months) (p = NS) in non-RPLN group vs RPLN group, respectively. In those who received CT only, the median OS was 7 months vs 8 months, while in those who received CT followed by CTRT, the median OS was 14 months vs 13 months (p = 0.65) in non-RPLN group vs RPLN group, respectively.

CONCLUSIONS:

Based on this analysis, we conclude that RPLN constitutes a major proportion of advanced non-metastatic GBC and has outcomes similar to those without RPLN if treated with radical intent. RPLN should not be considered a metastatic disease and should be treated with radical intent.

1,941

项与吉西他滨相关的新闻（医药）

2025-05-28

·药时空

PFS延长超6个月！LAG3单抗让PD-1疗效再升级

美国临床肿瘤学会（ASCO）年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。2025 ASCO年会即将于5月30日至6月3日在美国芝加哥正式召开。目前常规摘要已对外发布，不少国产新药表现亮眼。其中，维立志博的LBL-007携突破性数据再度登场，这已是该药连续第5年入选ASCO大会。LBL-007是一款靶向LAG3的全人源IgG4单克隆抗体，临床进度位居全球前三（唯一上市的LAG3靶向药物除外），也是同类抗体中首款被证实对鼻咽癌有效的抗体。此次披露的Ⅱ期数据验证了Lag3单抗在实体瘤治疗中，不仅可提升PD-1单抗的疗效（包括ORR、PFS以及潜在的OS获益），且安全性与依从性良好、毒性有限。由此出发，以LBL-007为代表的LAG3单抗将有潜力革新多种实体瘤联合疗法。01 ORR达83.3%，PFS提升幅度超70%LAG3，是一种免疫检查点受体，其在与配体结合后激活，可通过抑制T细胞功能促进肿瘤免疫逃逸。研究显示，LAG3抑制剂与PD-1/PD-L1药物联合使用可增强T细胞的抗肿瘤功能，在癌症治疗中展现强大的协同效应，为突破现有治疗瓶颈提供了全新方向。在机制上，PD-1和LAG3共表达时，可以通过不同途径联合驱动T细胞耗竭。在黑色素瘤小鼠模型中，与单独敲除PD-1或LAG3相比，同时敲除PD-1和LAG3的CD8+ T细胞表现出更强的肿瘤杀伤效应和存活能力，以及效应样和干扰素响应基因的富集，导致IFN-γ释放增强。也有临床试验表明，抗LAG3和抗PD-1联合治疗可以增强CD8+ T细胞受体信号传导能力，降低TCR激活的阈值，改变CD8+ T细胞分化模式，在保持耗竭特征的同时提高了细胞毒性。这些研究共同证实了LAG3和PD-1能够协同驱动T细胞耗竭，为联合免疫治疗提供了新的策略。LBL-007设计为靶向LAG3的独特表位，能以高亲和力与LAG3结合，并阻断LAG3与所有四种已识别免疫抑制配体（包括MHC-II、LSECtin、Gal-3及FGL-1）结合。与LAG3结合后，LBL-007诱导有效的细胞内吞作用，抑制细胞表面的LAG3表达，从而进一步阻断配体相互作用及增强免疫应答。图1：LBL-007及其与PD-1抗体联合使用的作用机制（来源：维立志博招股书）此次公布的LBL-007 II期临床试验采用四药联合方案，即LBL-007联合替雷利珠单抗（PD-1抗体）以及吉西他滨和顺铂（GP化疗方案）。研究结果显示，接受LBL-007、替雷利珠单抗和化疗联合治疗的患者，其客观缓解率（ORR）达到了83.3%，相较于仅使用替雷利珠单抗联合化疗的69.5%，提升了近20个百分点。这表明，LBL-007 的加入显著提高了复发性或转移性鼻咽癌的临床缓解率，实现肿瘤的缩小或稳定。更值得关注的是无进展生存期（PFS）的显著延长。联合LBL-007治疗组的中位PFS达到了15.8个月，相比替雷+化疗的历史数据9.6个月，足足延长了超过6个月，提升幅度超过70%。这一成果意味着患者在接受治疗后，能够更长时间地保持病情稳定，延缓疾病进展，极大地改善了患者的生存质量和预后。对于复发或转移性鼻咽癌患者而言，这无疑是一个巨大的福音，为他们赢得了更多宝贵的治疗窗口期。另外，LBL-007的OS数据虽然尚未成熟，但已显示出获益趋势，具备超越替雷利珠单抗+GP方案生存获益的潜力。此外，在食管鳞癌、头颈部鳞癌及鳞状非小细胞肺癌患者中也观察到较好的疗效，提示多种实体瘤治疗方案的潜力。特别在鳞状非小细胞肺癌患者中，LBL-007联用疗法ORR达到25.0%。02 停药比例低于PD-1+化疗联用方案，安全性与依从性良好在安全性方面，此前，LBL-007的安全性已在多项临床研究中得到验证。其中，在LBL-007联合特瑞普利单抗在治疗晚期实体瘤的Ib/II期临床研究中，该组合疗法展现出良好的安全性：3级以上治疗相关不良反应的发生率仅为11.3%，导致治疗终止的不良反应的发生率仅为8.8%，未发生治疗相关的死亡事件，未出现预期之外的不良事件。相较于relatlimab联用纳武利尤单抗方案（3级或4级治疗相关不良事件患者发生率18.9%），LBL-007联合方案凸显出耐受性优势。而此次披露的最新数据，也再次印证了LBL-007联用方案的良好安全性。研究数据显示，与单纯使用替雷利珠单抗联合化疗相比，加入LBL-007后，没有观察到新的不良反应信号。LBL-007联合治疗方案中停药比例为4.8%，低于替雷利珠单抗+化疗5.3%的历史数据，表明其安全性与依从性良好。作为全身内科治疗方案，化疗药物本身具备较强的全身毒性反应，可能引发一系列不良事件，长期使用化疗会导致3级及以上的急性中毒反应，如急性黏膜炎及大出血。最新数据表明LBL-007依从性良好，其加入并未改变整体的安全性轮廓，患者在接受治疗时，所面临的安全性风险主要仍来自化疗药物，而非LBL-007本身。总结：LBL-007的突破性进展成功验证了LAG3靶点在癌症治疗领域的价值，尤其是在提升PD-1疗效方面，或可解决PD-1耐药性这个重大难题，其适应症可扩展至其他LAG3高表达肿瘤（如非小细胞肺癌、结直肠癌）。基于上述出色的安全性和有效性数据，相关团队正在积极推进关键的Ⅲ期临床试验，以进一步验证这一联合疗法的优势。未来，该疗法有望改写全球治疗指南，引领肿瘤免疫治疗新时代。识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

ASCO会议临床结果临床2期临床1期

2025-05-28

·Insight数据库

全球首款 CD79B ADC 新适应症国内申报上市

5 月 28 日，CDE 官网显示，罗氏注射用维泊妥珠单抗（商品名：Polivy、优罗华）新适应症上市申请获受理。此前 2023 年 1 月，该产品已在中国获批两项适应症。来源：CDE 官网维泊妥珠单抗是罗氏开发的一款靶向 CD79B 的 ADC，2019 年 6 月以加速批准的方式在美国获批上市，联合苯达莫司汀+利妥昔单抗用于既往至少接受过 2 种治疗方案的 R/R DLBCL，目前已转为完全批准。2023 年 4 月，该产品 DLBCL 适应症被拓展至一线。2023 年 1 月，维泊妥珠单抗进入中国市场，适应症为：1）联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松适用于治疗既往未经治疗的 DLBCL 成人患者；2）联合苯达莫司汀和利妥昔单抗用于不适合接受造血干细胞移植的 R/R DLBCL 成人患者。今年 4 月，罗氏在一季度报中披露，2025 年将递交维泊妥珠单抗联合莫妥珠单抗（CD20/CD3 双抗）二线以上 DLBCL 适应症的上市申请。来源：罗氏财报作为全球唯一一款获批的 CD79B ADC，维泊妥珠单抗自上市以来，销售额一路高歌猛进，24 年成功跻身重磅炸弹行列。25 年第一季度，该产品销售额为 3.58 亿瑞士法郎，同比增长 42%。来源：Insight 数据库Insight 数据库显示，目前全球仅有 4 款 CD79B ADC 在研，除维泊妥珠单抗外，还有恒瑞 SHR-A1912（III 期）以及新港生物 NBT508（I 期）已进入临床阶段。来源：Insight 数据库今年 5 月，恒瑞在 ASCO 大会上公布了 SHR-A1912 与利妥昔单抗、吉西他滨和奥沙利铂 (R-GemOx) 联合治疗 R/R DLBCL 的 Ib/II 期临床数据。结果显示，1.8 mg/kg SHR-A1912 与 R-GemOx 联合用药耐受性良好，且安全性与其各成分一致。该联合用药表现出强大的抗肿瘤活性，具有快速且持久的疗效。封面来源：企业logo免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：月牙PR 稿对接：微信 insightxb投稿：微信 insightxb；邮箱 insight@dxy.cn

财报抗体药物偶联物ASCO会议上市批准临床1期

2025-05-28

·药智网

PD-1+LAG3联手“突围”

2025 ASCO年会召开在即，目前常规摘要已对外发布，不少国产新药表现亮眼。其中维立志博的LBL-007携突破性数据再度登场，这已是该药连续第5年入选ASCO大会。LBL-007是一款靶向LAG3的全人源IgG4单克隆抗体，临床进度位居全球前三（唯一上市的LAG3靶向药物除外），也是同类抗体中首款被证实对鼻咽癌有效的抗体。临床数据显示，LBL-007联合疗法一线治疗鼻咽癌患者，ORR高达83.3%，中位PFS延长至15.8个月，较现有标准方案大幅提升。凭借卓越的安全性与疗效，LBL-007有望成为复发或转移性鼻咽癌（R/M NPC）一线治疗的新标杆。显著提升的卓越疗效LAG3，是一种免疫检查点受体，其在与配体结合后激活，可通过抑制T细胞功能促进肿瘤免疫逃逸。研究显示，LAG3抑制剂与PD-1/PD-L1药物联合使用可增强T细胞的抗肿瘤功能，在癌症治疗中展现强大的协同效应，为突破现有治疗瓶颈提供了全新方向。在机制上，PD-1和LAG3共表达时，可以通过不同途径联合驱动T细胞耗竭。在黑色素瘤小鼠模型中，与单独敲除PD-1或LAG3相比，同时敲除PD-1和LAG3的CD8+T细胞表现出更强的肿瘤杀伤效应和存活能力，以及效应样和干扰素响应基因的富集，导致IFN-γ释放增强。也有临床试验表明，抗LAG3和抗PD-1联合治疗可以增强CD8+T细胞受体信号传导能力，降低TCR激活的阈值，改变CD8+T细胞分化模式，在保持耗竭特征的同时提高了细胞毒性。这些研究共同证实了LAG3和PD-1能够协同驱动T细胞耗竭，为联合免疫治疗提供了新的策略。LBL-007设计为靶向LAG3的独特表位，能以高亲和力与LAG3结合，并阻断LAG3与所有四种已识别免疫抑制配体（包括MHC-II、LSECtin、Gal-3及FGL-1）结合。与LAG3结合后，LBL-007诱导有效的细胞内吞作用，抑制细胞表面的LAG3表达，从而进一步阻断配体相互作用及增强免疫应答。图1 LBL-007及其与PD-1抗体联合使用的作用机制图片来源：维立志博招股书研究结果显示，接受LBL-007、替雷利珠单抗和化疗联合治疗的患者，其客观缓解率（ORR）达到了83.3%，相较于仅使用替雷利珠单抗联合化疗的69.5%，提升了近20个百分点。这表明，LBL-007的加入显著增强了肿瘤的缓解率，使更多患者能够从治疗中获益，实现肿瘤的缩小或稳定。更值得关注的是无进展生存期（PFS）的显著延长。联合LBL-007治疗组的中位PFS达到了15.8个月，相比替雷+化疗的历史数据9.6个月，足足延长了超过6个月，提升幅度超过70%。这一成果意味着患者在接受治疗后，能够更长时间地保持病情稳定，延缓疾病进展，极大地改善了患者的生存质量和预后。对于复发或转移性鼻咽癌患者而言，这无疑是一个巨大的福音，为他们赢得了更多宝贵的治疗窗口期。另外，LBL-007的OS数据虽然尚未成熟，但已显示出获益趋势，具备超越替雷利珠单抗+GP方案生存获益的潜力。经得起考验的坚实后盾安全性是新药临床试验的另一个核心关注点。此前，LBL-007的安全性已在多项临床研究中得到验证。其中，在LBL-007联合特瑞普利单抗在治疗晚期实体瘤的Ib/II期临床研究中，该组合疗法展现出良好的安全性：3级以上治疗相关不良反应的发生率仅为11.3%，导致治疗终止的不良反应的发生率仅为8.8%，未发生治疗相关的死亡事件，未出现预期之外的不良事件。相较于relatlimab联用纳武利尤单抗方案（3级或4级治疗相关不良事件患者发生率18.9%），LBL-007联合方案凸显出耐受性优势。ASCO 2025数据显示再次印证LBL-007联用方案的良好安全性。此次公布的LBL-007临床试验采用四药联合方案，即LBL-007联合替雷利珠单抗（PD-1抗体）以及吉西他滨和顺铂（GP化疗方案）。临床数据显示，与单纯使用替雷利珠单抗联合化疗相比，加入LBL-007后，没有观察到新的不良反应信号。LBL-007导致停药的比例非常低（4.8%)，甚至比替雷利珠单抗联合化疗方案还要低(5.3%)。化疗药物本身就具有较强的毒性反应，可能引发一系列不良事件。最新数据表明LBL-007依从性良好，其加入并未改变整体的安全性轮廓，患者在接受治疗时，所面临的安全性风险主要仍来自化疗药物，而非LBL-007本身。这一关键事实为临床医生和患者注入了一剂“强心针”。引领肿瘤免疫治疗新时代基于上述出色的安全性和有效性数据，相关团队正在积极推进关键的Ⅲ期临床试验，以进一步验证这一联合疗法的优势。随着Ⅲ期临床试验的推进，LBL-007联合替雷利珠单抗及化疗方案有望改写全球治疗指南，成为复发或转移性鼻咽癌一线治疗的新标准。而且，LBL-007的突破性进展也成功验证了LAG3靶点在癌症治疗领域的价值，其适应症或可扩展至其他LAG3高表达肿瘤（如非小细胞肺癌、结直肠癌），为更多患者点燃希望。声明：本内容仅用作医药行业信息传播，不代表药智网立场。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 紫菀合作、投稿 | 马老师 18323856316（同微信）阅读原文，是受欢迎的文章哦

ASCO会议临床结果免疫疗法临床1期

100 项与吉西他滨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02368	吉西他滨	L01BC05	DB00441

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床3期	-	RenovoRx, Inc.	2023-06-01
转移性胰腺导管腺癌	临床3期	澳大利亚	Panbela Therapeutics, Inc.	2022-08-04
局部晚期胰腺腺癌	临床3期	美国	RenovoRx, Inc.	2018-03-12
局部晚期胰腺腺癌	临床3期	比利时	RenovoRx, Inc.	2018-03-12
晚期鳞状细胞肺癌	临床3期	美国	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	比利时	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	加拿大	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	法国	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	德国	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	匈牙利	Sanofi	2010-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02807181 (SIRCCA, CTgov)	临床2/3期	不可切除的肝内胆管癌	89	gemcitabine+Cisplatin (Chemotherapy (Cisplatin-Gemcitabine))	鬱淵鏇簾衊構窪膚築襯(鹹糧選餘壓鹽齋糧獵餘) = 獵遞壓鹹糧繭膚繭襯鬱簾醖膚餘遞淵築願齋壓 (範積壓糧壓選網蓋鹽艱, 簾製齋襯築廠願觸淵鹹 ~ 願淵窪鏇襯製壓蓋鏇壓) 更多	-	2025-05-09
				Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)+gemcitabine+Cisplatin (Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine))	鬱淵鏇簾衊構窪膚築襯(鹹糧選餘壓鹽齋糧獵餘) = 餘觸齋鏇網淵淵衊觸構簾醖膚餘遞淵築願齋壓 (範積壓糧壓選網蓋鹽艱, 夢齋醖淵襯憲網遞壓鑰 ~ 艱醖構膚選蓋網願繭鹽) 更多
NCT04602078 (AUREA \| SOGUG-AUREA, CTgov)	临床2期	膀胱尿路上皮癌 \| 局部晚期尿路上皮癌 \| 转移性尿路上皮癌	82	Cisplatin 70 mg/m2+Gemcitabine 1000 mg/m2+Atezolizumab 1200 mg/m2	憲窪膚構壓鹹窪選構蓋 = 醖膚廠顧獵構齋夢簾鹽鑰膚蓋窪餘衊鹹願膚鑰 (簾膚艱選鬱積廠顧網獵, 鬱製壓簾觸鹹衊觸鹽淵 ~ 選鬱願壓淵範範願糧構) 更多	-	2025-04-24
ASCO_GU2025	N/A	非肌层浸润性膀胱肿瘤 Consensus subtyping models	143	Intravesical Bacillus Calmette-Guerin (BCG)	顧醖餘選淵窪選鹹築淵(蓋醖衊齋壓觸構鬱鹹壓) = 艱衊糧鑰醖構廠觸鏇糧壓鏇範製壓構壓膚顧觸 (餘構築繭鬱遞範網淵糧 )	积极	2025-02-13
				Sequential intravesical gemcitabine and docetaxel (Gem/Doce)	顧醖餘選淵窪選鹹築淵(蓋醖衊齋壓觸構鬱鹹壓) = 齋築鬱積鹹遞繭構鹽廠壓鏇範製壓構壓膚顧觸 (餘構築繭鬱遞範網淵糧 )
ASCO_GU2025	N/A	非肌层浸润性膀胱肿瘤	30	Intravesical Gemcitabine and Docetaxel	齋衊製衊鬱觸簾齋顧鏇(鏇壓壓壓簾鬱鹽蓋糧鏇) = 繭構遞淵構觸積願鏇鏇壓網廠網醖鹽構顧簾遞 (製襯築餘餘衊衊願觸艱 ) 更多	积极	2025-02-13
NCT01972919 (CTgov)	临床2期	不能切除性胰腺癌	23	Radiation Therapy+Gemcitabine+Capecitabine	觸醖鑰獵憲積遞廠觸鬱 = 遞觸淵壓簾鬱獵網範鏇顧積餘顧廠顧淵鑰鑰觸 (蓋艱糧積築憲築選夢鹽, 顧襯顧遞膚壓簾選鬱廠 ~ 鏇繭選廠鹹願顧艱窪鹽) 更多	-	2025-02-10
ACTRN12623000223639 (ASCO_GI2025)	N/A	晚期胰腺导管腺癌	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	衊簾獵鹽艱範夢網廠範(齋窪壓鹹憲餘襯艱壓膚) = 蓋淵壓糧觸鑰鹹鏇蓋淵繭衊範餘顧艱衊蓋憲衊 (壓構顧積艱窪願憲醖膚 )	积极	2025-01-23
NCT03257033 (TIGeR-PaC, ASCO_GI2025)	临床3期	局部晚期胰腺腺癌	19	Intra-arterial gemcitabine	餘艱範積製憲糧鬱醖簾(廠範膚製壓製窪鬱膚鹹) = 鹽襯廠網觸鏇選獵選構網構糧艱鑰醖膚繭製鏇 (築獵鏇觸製獵鹹簾餘餘 )	积极	2025-01-23
				Intravenous gemcitabine	餘艱範積製憲糧鬱醖簾(廠範膚製壓製窪鬱膚鹹) = 壓淵廠餘範壓積簾製窪網構糧艱鑰醖膚繭製鏇 (築獵鏇觸製獵鹹簾餘餘 )
ASCO_GI2025	N/A	胰腺导管腺癌 DNA methylation changes	184	Gemcitabine	壓獵膚齋憲窪鏇襯簾蓋(範範顧鹽蓋鹹製餘窪淵) = 積獵製蓋鑰齋艱構獵遞鬱夢衊壓網壓簾範襯鑰 (壓鹽繭餘襯鹹鏇積遞窪 ) 更多	-	2025-01-23
				Fluorouracil (5-FU)	壓獵膚齋憲窪鏇襯簾蓋(範範顧鹽蓋鹹製餘窪淵) = 餘構憲顧夢糧網顧積網鬱夢衊壓網壓簾範襯鑰 (壓鹽繭餘襯鹹鏇積遞窪 )
NCT04229004 (Precision Promise (PrP), ASCO_GI2025)	临床2/3期	转移性胰腺癌二线	317	Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA)	鬱膚願衊夢顧鏇範蓋製(蓋艱顧積積鏇願鹽廠鬱): HR = 1.18 (95% CI, 0.88 ~ 1.56), P-Value = 0.14 更多	不佳	2025-01-23
				Gemcitabine/Abraxane (GA)
ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Glofitamab with Gemcitabine and Oxaliplatin	廠鏇簾獵蓋廠選壓範鑰(鬱艱窪窪鑰鹹憲憲製願) = 蓋襯築構鹹齋網鹹繭願網憲鑰淵艱積衊簾醖網 (淵壓顧衊構選築鏇鑰膚, NA) 更多	-	2024-12-09
				Rituximab with Gemcitabine and Oxaliplatin	廠鏇簾獵蓋廠選壓範鑰(鬱艱窪窪鑰鹹憲憲製願) = 醖繭餘襯積艱餘鏇積膚網憲鑰淵艱積衊簾醖網 (淵壓顧衊構選築鏇鑰膚, NA) 更多